- New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?
-
Lim YS
- KMID: 2538208
- Clin Mol Hepatol.
- 2023 Jan;29(1):118-119.
- doi: 10.3350/cmh.2022.0413
-
- CITED
-
- Close
- SHARE
-
- Close
- Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
-
Liang LY, Wong VWS, Wong GLH, Yip TCF
- KMID: 2538207
- Clin Mol Hepatol.
- 2023 Jan;29(1):113-117.
- doi: 10.3350/cmh.2022.0333
-
- CITED
-
- Close
- SHARE
-
- Close
- Report on the External Quality Assessment Scheme for Molecular Microbiology, Hepatitis Virus 1, 2 (2016–2021)
-
Moon HW, Lee TH, Seo JD
- KMID: 2538677
- Lab Med Qual Assur.
- 2022 Dec;44(4):191-198.
- doi: 10.15263/jlmqa.2022.44.4.191
The clinical demand for molecular tests is increasing and thus, the need for quality control is also increasing. The Korean Association of External Quality Assessment Service has operated a test... -
- CITED
-
- Close
- SHARE
-
- Close
- Updated Treatment Guidelines for Chronic Hepatitis B
-
An J
- KMID: 2536632
- Korean J Med.
- 2022 Dec;97(6):353-360.
- doi: 10.3904/kjm.2022.97.6.353
Chronic hepatitis B virus (HBV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma in Korea. While the prevalence of HBV infection is gradually declining in Korea, 3... -
- CITED
-
- Close
- SHARE
-
- Close
- Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus
-
Wu D, Rao Q, Xie Z, Zhu X, Che Y, Wu J, Gao H, Zhang J, Hou Z, Cheng X, Sun Z
- KMID: 2534354
- Clin Mol Hepatol.
- 2022 Oct;28(4):912-925.
- doi: 10.3350/cmh.2022.0121
Background/Aims: Acute-on-chronic liver failure (ACLF) is a catastrophic illness. Few studies investigated the prognostic value of vitamin D-binding protein (VDBP) for hepatitis B virus (HBV)-related ACLF (HBV-ACLF) resulted in conflicting... -
- CITED
-
- Close
- SHARE
-
- Close
- RNA interference as a novel treatment strategy for chronic hepatitis B infection
-
Hui RWH, Mak LY, Seto WK, Yuen MF
- KMID: 2531368
- Clin Mol Hepatol.
- 2022 Jul;28(3):408-424.
- doi: 10.3350/cmh.2022.0012
Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment
-
Ahn SM, Choi J, Ye BD, Yang SK, Oh JS, Kim Y, Lee C, Yoo B, Park SH, Hong S
- KMID: 2531239
- Gut Liver.
- 2022 Jul;16(4):567-574.
- doi: 10.5009/gnl210204
Background/Aims: Anti-hepatitis B virus (HBV) therapy is required for patients with HBV infection receiving biologics because of the high risk of HBV reactivation. However, it is unclear when to start... -
- CITED
-
- Close
- SHARE
-
- Close
- Metabolic Risk Factors Are Associated with the Disease Severity and Prognosis of Hepatitis B Virus-Related Acute on Chronic Liver Failure
-
Chen L, Dai J, Xie Q, Wang X, Cai W
- KMID: 2529853
- Gut Liver.
- 2022 May;16(3):456-464.
- doi: 10.5009/gnl210449
Background/Aims: Metabolic risk factors could accelerate hepatitis B virus (HBV)-related mortality; however, their impacts on disease severity in HBV-related acute on chronic liver failure (HBV-ACLF) patients remain unexplored. In this... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
-
Lee JM, Wei SC, Lee KM, Ye BD, Mao R, Kim HS, Park SJ, Park SH, Oh EH, Im JP, Jang BI, Kim DB, Takeuchi K
- KMID: 2529846
- Gut Liver.
- 2022 May;16(3):396-403.
- doi: 10.5009/gnl210081
Background/Aims: Little is known about the clinical course of hepatitis B virus (HBV)-infected patients undergoing anti-tumor necrosis factor α (TNF-α) therapy for inflammatory bowel disease (IBD). We aimed to investigate... -
- CITED
-
- Close
- SHARE
-
- Close
- A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients
-
Kim HJ, Kim JH, Yeon JE, Seo YS, Jang JW, Cho YK, Jang BK, Han BH, Lee C, Lee JH, Yoon JH, Kim KM, Kim MY, Kim DY, Park NH, Cho EY, Lee JS, Lee JW, Kim IH, Song BC, Lee BS, Kwon OS
- KMID: 2527452
- J Korean Med Sci.
- 2022 Mar;37(11):e92.
- doi: 10.3346/jkms.2022.37.e92
Background: Tenofovir disoproxil fumarate (TDF, Viread® ) had been used as a standard treatment option of chronic hepatitis B (CHB). This clinical trial was conducted to evaluate the efficacy and... -
- CITED
-
- Close
- SHARE
-
- Close
- Identification of key genes and carcinogenic pathways in hepatitis B virus-associated hepatocellular carcinoma through bioinformatics analysis
-
Kim SH, Hwang S, Song GW, Jung DH, Moon DB, Yang JD, Yu HC
- KMID: 2526833
- Ann Hepatobiliary Pancreat Surg.
- 2022 Feb;26(1):58-68.
- doi: 10.14701/ahbps.21-108
Backgrounds/Aims: Mechanisms for the development of hepatocellular carcinoma (HCC) in hepatitis B virus (HBV)-infected patients remain unclear. The aim of the present study was to identify genes and pathways involved... -
- CITED
-
- Close
- SHARE
-
- Close
- Protectivity and safety following recombinant hepatitis B vaccine with different source of bulk compared to hepatitis B (Bio Farma) vaccine in Indonesia
-
Nency YM, Rahmadi FA, M, Anantyo DT, Farhanah N, Hapsari R, Farida H, Sadhana U, Djagat H, Kristina TN, Juniarto AZ, Puspita M, Sari RM, Bachtiar NS
- KMID: 2534926
- Clin Exp Vaccine Res.
- 2022 Jan;11(1):43-52.
- doi: 10.7774/cevr.2022.11.1.43
Purpose Indonesia, a high populous and the second-highest country in epidemicity of hepatitis B in South-East Asia require maintaining its capacity of monovalent hepatitis B production to keep up with both... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatocellular carcinoma and cancer-related mortality after kidney transplantation with rituximab treatment
-
Lee H, Kim YH, Lim SJ, Ko Y, Shin S, Jung JH, Baek C, Kim H, Park SK, Kwon H
- KMID: 2523770
- Ann Surg Treat Res.
- 2022 Jan;102(1):55-63.
- doi: 10.4174/astr.2022.102.1.55
Purpose: There are increased therapeutic usages of rituximab in kidney transplantation (KT). However, few studies have evaluated the effect of rituximab on cancer development following KT. This study aimed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus
-
Kim SW, Yoon JS, Lee M, Cho Y
- KMID: 2523867
- Clin Mol Hepatol.
- 2022 Jan;28(1):17-30.
- doi: 10.3350/cmh.2021.0093
Hepatitis B virus (HBV) affects approximately 250 million patients worldwide, resulting in the progression to cirrhosis and hepatocellular carcinoma, which are serious public health problems. Although universal vaccination programs exist,... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B virus X Protein Promotes Liver Cancer Progression through Autophagy Induction in Response to TLR4 Stimulation
-
- KMID: 2522157
- Immune Netw.
- 2021 Oct;21(5):e37.
- doi: 10.4110/in.2021.21.e37
Hepatitis B virus X (HBx) protein has been reported as a key protein regulating the pathogenesis of HBV-induced hepatocellular carcinoma (HCC). Recent evidence has shown that HBx is implicated in... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B virus X Protein Promotes Liver Cancer Progression through Autophagy Induction in Response to TLR4 Stimulation
-
- KMID: 2522156
- Immune Netw.
- 2021 Oct;21(5):e37.
- doi: 10.4110/in.2021.21.e37
Hepatitis B virus X (HBx) protein has been reported as a key protein regulating the pathogenesis of HBV-induced hepatocellular carcinoma (HCC). Recent evidence has shown that HBx is implicated in... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B virus X Protein Promotes Liver Cancer Progression through Autophagy Induction in Response to TLR4 Stimulation
-
Son J, Kim MJ, Lee JS, Kim JY, Chun E, Lee KY
- KMID: 2522155
- Immune Netw.
- 2021 Oct;21(5):e37.
- doi: 10.4110/in.2021.21.e37
Hepatitis B virus X (HBx) protein has been reported as a key protein regulating the pathogenesis of HBV-induced hepatocellular carcinoma (HCC). Recent evidence has shown that HBx is implicated in... -
- CITED
-
- Close
- SHARE
-
- Close
- History and future of hepatitis B virus control in South Korea
-
Kim DY
- KMID: 2520845
- Clin Mol Hepatol.
- 2021 Oct;27(4):620-622.
- doi: 10.3350/cmh.2021.0277
-
- CITED
-
- Close
- SHARE
-
- Close
- Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea
-
Kim KD, Lee JE, Kim JM, Lee O, Hwang NY, Rhu J, Choi GS, Kim K, Joh JW
- KMID: 2520843
- Clin Mol Hepatol.
- 2021 Oct;27(4):603-615.
- doi: 10.3350/cmh.2021.0137
Background/Aims: Hepatitis B core antibody (anti-HBc)-positive donors are used as an extended donor pool, and current guidelines recommend the usage of nucleos(t)ide analogues (NAs) as prophylaxis for preventing de novo... -
- CITED
-
- Close
- SHARE
-
- Close
- Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma
-
Wu JW, Kao JH, Tseng TC
- KMID: 2520835
- Clin Mol Hepatol.
- 2021 Oct;27(4):524-534.
- doi: 10.3350/cmh.2021.0012
Patients with chronic hepatitis B virus (HBV) infection are at risk of developing hepatocellular carcinoma (HCC), and serum markers reflecting viral replication are potential predictors for HCC development. Besides the... -
- CITED
-
- Close
- SHARE
-
- Close
